摘要
人类原发性免疫缺陷病(PIDs)是一大类罕见疾病,具有很强的遗传和表型异质性。遗传定义了大量的PID,这对于理解疾病的分子基础和精准医学的发展具有重要影响。由于所涉及的过程的长度和成本,长期以来已经发现和开发用于罕见疾病的新疗法。由于刺激性的监管和支持性报销环境使得可行的商业模式成为可能,利息增加了。生物医学和计算科学的进步使得能够开发合理的,设计的方法来识别已经批准的药物的新指示,从而允许更快地递送新药物。药物重新定位基于疾病的临床类比或理解药物作用的分子模式和疾病的机制。所有这些都是精准医学发展的基础。
关键词: 药物重新定位,重新定位,原发性免疫缺陷病; 儿科,新疗法,罕见疾病。
Current Medicinal Chemistry
Title:Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine
Volume: 25 Issue: 24
关键词: 药物重新定位,重新定位,原发性免疫缺陷病; 儿科,新疗法,罕见疾病。
摘要: Human primary immunodeficiency diseases (PIDs) are a large group of rare diseases and are characterized by a great genetic and phenotypic heterogeneity. A large subset of PIDs is genetically defined, which has a crucial impact for the understanding of the molecular basis of disease and the development of precision medicine.
Discovery and development of new therapies for rare diseases has long been de-privileged due to the length and cost of the processes involved. Interest has increased due to stimulatory regulatory and supportive reimbursement environments enabling viable business models.
Advancements in biomedical and computational sciences enable the development of rational, designed approaches for identification of novel indications of already approved drugs allowing faster delivery of new medicines. Drug repositioning is based either on clinical analogies of diseases or on understanding of the molecular mode of drug action and mechanisms of the disease. All of these are the basis for the development of precision medicine.
Export Options
About this article
Cite this article as:
Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine, Current Medicinal Chemistry 2018; 25 (24) . https://dx.doi.org/10.2174/0929867324666170830101215
DOI https://dx.doi.org/10.2174/0929867324666170830101215 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autoantibodies in Systemic Lupus: Quite a Lot or Just a Few?
Current Rheumatology Reviews Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Pharmacologic Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus
Current Drug Targets Exercise Induced Cardioprotection: An Overview of a Unique Form of Preconditioning
Current Cardiology Reviews The Role of Melanin to Dissociate Oxygen from Water to Treat Retinopathy of Prematurity
Central Nervous System Agents in Medicinal Chemistry Selenium and Autoimmune Diseases: A Review Article
Current Rheumatology Reviews Phytochemical, Anti-diabetic and Cardiovascular Properties of Urtica dioica L. (Urticaceae): A Review
Mini-Reviews in Medicinal Chemistry Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations
Current Genomics Outcome of 27 Patients with Granulomatosis with Polyangiitis (Wegener's Granulomatosis) Patients in Iran
Current Respiratory Medicine Reviews Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases
Current Medicinal Chemistry Neuroimaging Features of Acquired Metabolic and Toxic Encephalopathies
Current Medical Imaging The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews MEFV Mutation Carriers and Diseases Other than Familial Mediterranean Fever: Proved and Non-Proved Associations; Putative Biological Advantage
Current Drug Targets - Inflammation & Allergy Cytostatic Properties of Some Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type I Receptor Antagonists
Current Pharmaceutical Design Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies
Current Drug Delivery Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Anti-Inflammatory Therapeutic Approaches to Reduce Acute Atherosclerotic Complications
Current Pharmaceutical Biotechnology Oxidative Stress: Meeting Multiple Targets in Pathogenesis of Vascular Endothelial Dysfunction
Current Drug Targets